A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus Infection

Trial Profile

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus Infection

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Vapendavir (Primary)
  • Indications Rhinovirus infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Aviragen Therapeutics
  • Most Recent Events

    • 21 Apr 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Apr 2017.
    • 04 Apr 2017 Status changed from not yet recruiting to withdrawn prior to enrolment, according to an Aviragen Therapeutics media release, .
    • 02 Feb 2017 According to an Aviragen Therapeutics media release, company plans to initiate this trial in Q1 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top